Wave Life Sciences Ltd

For the period ended Mar 31, 2024. Filed May 10, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2024 · Filed May 10, 2024

WVE$3.48+3.4%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Unaudited Consolidated Balance Sheets

(In thousands, except share amounts)

	March 31, 2024	December 31, 2023
Assets
Current assets:
Cash and cash equivalents	$180,922	$200,351
Accounts receivable	—	21,086
Prepaid expenses	11,139	9,912
Other current assets	4,706	4,024
Total current assets	196,767	235,373
Long-term assets:
Property and equipment, net of accumulated depreciation of $43,687 and $42,709 as of March 31, 2024 and December 31, 2023, respectively	12,418	13,084
Operating lease right-of-use assets	21,502	22,637
Restricted cash	3,715	3,699
Other assets	868	156
Total long-term assets	38,503	39,576
Total assets	$235,270	$274,949
Liabilities, Series A preferred shares, and shareholders’ equity
Current liabilities:
Accounts payable	$11,730	$12,839
Accrued expenses and other current liabilities	6,621	16,828
Current portion of deferred revenue	140,586	150,059
Current portion of operating lease liability	6,936	6,714
Total current liabilities	165,873	186,440
Long-term liabilities:
Deferred revenue, net of current portion	12,536	15,601
Operating lease liability, net of current portion	23,598	25,404
Total long-term liabilities	36,134	41,005
Total liabilities	$202,007	$227,445
Series A preferred shares, no par value; 3,901,348 shares issued and outstanding at March 31, 2024 and December 31, 2023	$7,874	$7,874
Shareholders’ equity:
Ordinary shares, no par value; 122,321,384 and 119,162,234 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	$949,877	$935,367
Additional paid-in capital	132,118	129,237
Accumulated other comprehensive loss	(198)	(124)
Accumulated deficit	(1,056,408)	(1,024,850)
Total shareholders’ equity	$25,389	$39,630
Total liabilities, Series A preferred shares, and shareholders’ equity	$235,270	$274,949

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.